%0 Journal Article
%T IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?
%A Jakub Tomala
%A Marek Kovar
%J Archive of "Oncoimmunology".
%D 2016
%R 10.1080/2162402X.2015.1102829
%X The in vivo biological activity of IL-2 can be dramatically increased by complexing with anti-IL-2 mAb. Moreover, IL-2/anti-IL-2 mAb immunocomplexes selectively stimulate different subsets of immune cells, depending on the clone of anti-IL-2 mAb that is used. Thus, IL-2/S4B6 mAb complexes strongly stimulate CD122high populations, namely NK and memory CD8+ T cells. They also intermediately stimulate Treg cells. Conversely, IL-2/JES6.1 mAb immunocomplexes have no stimulatory activity for CD122high populations. However, they potently and highly selectively stimulate CD25+ cells (i.e., Treg and activated T cells). IL-2/S4B6 mAb immunocomplexes have also been shown to possess antitumor activity in various mouse tumor models
%K Anti-IL-2 mAb
%K cancer immunotherapy
%K IL-2
%K immunocomplexes
%K selective stimulatory activity
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839359/